Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03819465 · ClinicalTrials.gov registry record · Phase 1
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
A Phase 1 study of Metastatic Non-Small Cell Lung Cancer (NSCLC), sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 175
- Enrollment target
- 20
- Study locations
NCT03819465 is a Phase 1 study of Metastatic Non-Small Cell Lung Cancer (NSCLC) that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 175 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT03819465, a Phase 1 study of Metastatic Non-Small Cell Lung Cancer (NSCLC), is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 175 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
Conditions Studied
Interventions
- DRUG Pemetrexed
- DRUG Durvalumab
- DRUG Danvatirsen
- DRUG Oleclumab
- DRUG MEDI5752
Study Locations (20)
Other
- Research Site - Salzburg
- Research Site - Vienna
- Research Site - Edegem
- Research Site - Bialystok
- Research Site - Bydgoszcz
- Research Site - Gdansk
- Research Site - Grudziądz
- Research Site - Lodz
- Research Site - Olsztyn
- Research Site - Tomaszów Mazowiecki
- Research Site - Warsaw
- Research Site - Wroclaw
- Research Site - Krasnoyarsk
- Research Site - Moscow
- Research Site - Saint Petersburg
- Research Site - Saint Petersburg
- Research Site - Cheongju-si
Iowa
- Research Site - Iowa City
Pennsylvania
- Research Site - Pittsburgh
Tennessee
- Research Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2018-12-27 |
| Est. Completion | 2026-03-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03819465
The ClinicalTrials.gov registry entry for NCT03819465 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Non-Small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 5 interventions - of which Pemetrexed is the first listed.
NCT03819465 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Iowa, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03819465 about?
NCT03819465 is a clinical study titled "A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC". This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
What is the current status of trial NCT03819465?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2018-12-27. Estimated completion is 2026-03-26.
What conditions does trial NCT03819465 study?
This clinical trial studies the following conditions: Metastatic Non-Small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT03819465?
The interventions under investigation include: Pemetrexed (DRUG), Durvalumab (DRUG), Danvatirsen (DRUG), Oleclumab (DRUG), MEDI5752 (DRUG).
Who is sponsoring clinical trial NCT03819465?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03819465 being conducted?
This trial has 20 study locations across Iowa, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.